Comprehensive Pharmacological Study of Moringa oleifera: Anti-Diabetic and Anti-Cancer Potential

Abstract

Moringa oleifera is a well-known medicinal plant recognized for its diverse pharmacological activities, particularly in the 
management of metabolic and proliferative disorders. The present study investigates its anti-diabetic and anti-cancer potential 
using in vitro models. The anti-diabetic activity was evaluated through the α-amylase inhibition assay, which measures the 
ability of the plant extract to inhibit carbohydrate-hydrolyzing enzymes and thereby reduce postprandial hyperglycemia. The 
ethanolic extract of Moringa oleifera leaves exhibited significant enzyme inhibition, reaching up to 78% at higher 
concentrations, indicating strong hypoglycemic potential. 
The anti-cancer activity was assessed using the MTT assay on MCF-7 human breast cancer cell lines. The extract demonstrated 
dose-dependent cytotoxicity, with a notable decrease in cell viability and an IC₅₀ value of approximately 55 µg/mL, suggesting 
moderate anticancer efficacy. Phytochemical screening revealed the presence of bioactive compounds such as flavonoids, 
alkaloids, phenolics, tannins, and saponins, which are known to contribute to antioxidant, enzyme inhibitory, and apoptosis
inducing properties. 
The dual activity observed may be attributed to the synergistic action of these phytoconstituents, which target common 
pathways such as oxidative stress and inflammation involved in both diabetes and cancer. These findings support the potential 
of Moringa oleifera as a natural, cost-effective therapeutic agent. However, further in vivo studies and clinical trials are 
required to validate its safety, efficacy, and mechanism of action for pharmaceutical applications [1-8,22,29].